Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented pivotal Phase II study results for their next-generation selective RET inhibitor, lunbotinib fumarate, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study focused on patients with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The trial included 71 pre-treated patients and 92 treatment-naïve patients, showing an objective response rate of 81.3% in treatment-naïve and 87.1% in pre-treated patients. The drug demonstrated significant efficacy, particularly in patients with central nervous system metastases, achieving a 30% intracranial complete response rate. Lunbotinib fumarate was well tolerated, with minimal treatment-related adverse events leading to discontinuation. 
